<ul>
<li>三家医疗巨头刚刚提高了股息——谁支付得最多</li>
</ul>
<p>根据 MarketBeat 的股票筛选工具，Eli Lilly and Company、Pfizer、Bristol Myers Squibb、AbbVie、Gemini Therapeutics、Novo Nordisk A/S 和 Cytokinetics 是今天值得关注的七只制药股票。制药股票是指那些研究、开发、生产和销售处方药、疫苗及相关医疗产品的公司的公开交易股票。对于投资者而言，这些股票受临床试验结果、监管批准、专利生命周期和医疗政策的驱动，这可能创造出可观的增长潜力，但也伴随着高波动性和风险。这些公司在过去几天内的制药股票交易量最高。</p>
<p>获取 <strong>Eli Lilly and Company</strong> 的提醒：</p>
<h2>Eli Lilly and Company (LLY)</h2>
<p>Eli Lilly and Company 在全球范围内发现、开发和销售人用药物。该公司提供 Basaglar、Humalog、Humalog Mix 75/25、Humalog U-100、Humalog U-200、Humalog Mix 50/50、胰岛素 lispro、胰岛素 lispro 原料、胰岛素 lispro 混合 75/25、Humulin、Humulin 70/30、Humulin N、Humulin R 和 Humulin U-500 用于糖尿病；Jardiance、Mounjaro 和 Trulicity 用于 2 型糖尿病；Zepbound 用于肥胖。</p>
<ul>
<li>Pfizer 加大对减肥药物的投资</li>
</ul>
<p>阅读我们关于 LLY 的最新研究报告</p>
<h2>Pfizer (PFE)</h2>
<p>Pfizer Inc.在美国、欧洲及国际上发现、开发、制造、营销、分销和销售生物制药产品。该公司在多个治疗领域提供药物和疫苗，包括心血管代谢、偏头痛和女性健康，品牌包括 Eliquis、Nurtec ODT/Vydura、Zavzpret 和 Premarin 系列；针对未满足医疗需求的传染病，品牌包括 Prevnar 系列、Abrysvo、Nimenrix、FSME/IMMUN-TicoVac 和 Trumenba；以及 COVID-19 的预防和治疗，以及潜在的未来 mRNA 和抗病毒产品，品牌包括 Comirnaty 和 Paxlovid。</p>
<ul>
<li>黄金交叉警报：三只具有重大上涨潜力的股票</li>
</ul>
<p>阅读我们关于 PFE 的最新研究报告</p>
<h2>Bristol Myers Squibb (BMY)</h2>
<p>Bristol-Myers Squibb Company 在全球范围内发现、开发、许可、制造、营销、分销和销售生物制药产品。它提供用于血液学、肿瘤学、心血管、免疫学、纤维化和神经科学疾病的产品。该公司的产品包括 Eliquis，用于降低非瓣膜性心房颤动患者中风/全身栓塞的风险，以及治疗深静脉血栓/肺栓塞；Opdivo 用于多种抗癌适应症，包括膀胱癌、血液癌、结直肠癌、头颈癌、肾细胞癌、肝细胞癌、肺癌、黑色素瘤、胸膜间皮瘤、胃癌和食道癌；Pomalyst/Imnovid 用于多发性骨髓瘤；Orencia 用于活动性类风湿关节炎和银屑病关节炎；Sprycel 用于治疗费城染色体阳性慢性髓性白血病。</p>
<p>阅读我们关于 BMY 的最新研究报告</p>
<h2>AbbVie (ABBV)</h2>
<p>AbbVie Inc.在全球范围内发现、开发、制造和销售药物。该公司提供 Humira，一种用于自身免疫性和肠道贝赫切特病及脓皮病坏死的注射剂；Skyrizi 用于治疗中度至重度斑块型银屑病、银屑病性疾病和克罗恩病；Rinvoq 用于治疗类风湿关节炎和银屑病关节炎、强直性脊柱炎、特应性皮炎、轴性脊柱关节炎、溃疡性结肠炎和克罗恩病；Imbruvica 用于治疗成人血癌；Epkinly 用于治疗淋巴瘤；Elahere 用于治疗癌症；Venclexta/Venclyxto 用于治疗血癌。</p>
<p>阅读我们关于 ABBV 的最新研究报告</p>
<h2>Gemini Therapeutics (GMTX)</h2>
<p>Gemini Therapeutics, Inc.是一家临床阶段的精准医学公司，致力于开发用于治疗基因定义的年龄相关性黄斑变性（AMD）的各种治疗化合物。其主要候选药物是 GEM103，一种重组人补体因子 H 蛋白，用于治疗干性 AMD 患者。</p>
<p>阅读我们关于 GMTX 的最新研究报告</p>
<h2>Novo Nordisk A/S (NVO)</h2>
<p>Novo Nordisk A/S 及其子公司从事药品的研究与开发、制造和分销，覆盖欧洲、中东、非洲、中国大陆、香港、台湾、北美及国际市场。它分为两个部门，糖尿病和肥胖护理，以及罕见疾病。</p>
<p>阅读我们关于 NVO 的最新研究报告</p>
<h2>Cytokinetics (CYTK)</h2>
<p>Cytokinetics, Incorporated 是一家晚期生物制药公司，专注于发现、开发和商业化肌肉激活剂和抑制剂，作为潜在的治疗方案。该公司开发的小分子药物候选者主要旨在影响肌肉功能和收缩性。</p>
<p>阅读我们关于 CYTK 的最新研究报告</p>
<h2>进一步阅读</h2>
<ul>
<li>MarketBeat 在 2025 年 12 月的五大股票推荐</li>
<li>RKLB、ASTS、TDG：内部人士正在出售这三只航天股票</li>
<li>Instacart 被监控定价...但投资者并不在意</li>
<li>Broadcom 刚刚提高了股息——但这并不是唯一一个发出强劲信号的公司</li>
<li>亚马逊现在的配送推动可能提升其 2026 年展望</li>
<li>2026 年值得关注的五只小型股，投资者正在从大型科技股中撤出</li>
</ul>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1000 美元在 Eli Lilly and Company 吗？</h2>
<p>在考虑 Eli Lilly and Company 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买...而 Eli Lilly and Company 并不在名单上。</p>
<p>虽然礼来目前在分析师中被评为适度买入，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

百时美施贵宝

礼来

<p>MarketBeat 的股票筛选工具突出了七只值得关注的制药股票：礼来、辉瑞、百时美施贵宝、艾伯维、双子治疗、诺和诺德和细胞动力学。这些股票受到临床试验结果、监管批准和医疗政策的推动，具有增长潜力，但也伴随高波动性。礼来、辉瑞和百时美施贵宝最近提高了股息，显示出其强劲的表现。投资者应考虑这些股票的潜在上涨空间</p>

<ul>
<li>3 Healthcare Giants Just Raised Dividends—Here’s Who Pays the Most</li>
</ul>
<div class="lb-trans"><ul>
<li>三家医疗巨头刚刚提高了股息——谁支付得最多</li>
</ul>
</div><p>Eli Lilly and Company, Pfizer, Bristol Myers Squibb, AbbVie, Gemini Therapeutics, Novo Nordisk A/S, and Cytokinetics are the seven Pharmaceutical stocks to watch today, according to MarketBeat's stock screener tool. Pharmaceutical stocks are publicly traded shares of companies that research, develop, manufacture, and sell prescription drugs, vaccines, and related medical products. For investors, these stocks are driven by clinical-trial results, regulatory approvals, patent lifecycles, and healthcare policy, which can create substantial growth potential but also high volatility and risk. These companies had the highest dollar trading volume of any Pharmaceutical stocks within the last several days.</p>
<div class="lb-trans"><p>根据 MarketBeat 的股票筛选工具，Eli Lilly and Company、Pfizer、Bristol Myers Squibb、AbbVie、Gemini Therapeutics、Novo Nordisk A/S 和 Cytokinetics 是今天值得关注的七只制药股票。制药股票是指那些研究、开发、生产和销售处方药、疫苗及相关医疗产品的公司的公开交易股票。对于投资者而言，这些股票受临床试验结果、监管批准、专利生命周期和医疗政策的驱动，这可能创造出可观的增长潜力，但也伴随着高波动性和风险。这些公司在过去几天内的制药股票交易量最高。</p>
</div><p>Get <strong>Eli Lilly and Company</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Eli Lilly and Company</strong> 的提醒：</p>
</div><h2>Eli Lilly and Company (LLY)</h2>
<div class="lb-trans"><h2>Eli Lilly and Company (LLY)</h2>
</div><p>Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.</p>
<div class="lb-trans"><p>Eli Lilly and Company 在全球范围内发现、开发和销售人用药物。该公司提供 Basaglar、Humalog、Humalog Mix 75/25、Humalog U-100、Humalog U-200、Humalog Mix 50/50、胰岛素 lispro、胰岛素 lispro 原料、胰岛素 lispro 混合 75/25、Humulin、Humulin 70/30、Humulin N、Humulin R 和 Humulin U-500 用于糖尿病；Jardiance、Mounjaro 和 Trulicity 用于 2 型糖尿病；Zepbound 用于肥胖。</p>
</div><ul>
<li>Pfizer Adds to Its Big Bet on Weight Loss Drugs</li>
</ul>
<div class="lb-trans"><ul>
<li>Pfizer 加大对减肥药物的投资</li>
</ul>
</div><p>Read Our Latest Research Report on LLY</p>
<div class="lb-trans"><p>阅读我们关于 LLY 的最新研究报告</p>
</div><h2>Pfizer (PFE)</h2>
<div class="lb-trans"><h2>Pfizer (PFE)</h2>
</div><p>Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.</p>
<div class="lb-trans"><p>Pfizer Inc.在美国、欧洲及国际上发现、开发、制造、营销、分销和销售生物制药产品。该公司在多个治疗领域提供药物和疫苗，包括心血管代谢、偏头痛和女性健康，品牌包括 Eliquis、Nurtec ODT/Vydura、Zavzpret 和 Premarin 系列；针对未满足医疗需求的传染病，品牌包括 Prevnar 系列、Abrysvo、Nimenrix、FSME/IMMUN-TicoVac 和 Trumenba；以及 COVID-19 的预防和治疗，以及潜在的未来 mRNA 和抗病毒产品，品牌包括 Comirnaty 和 Paxlovid。</p>
</div><ul>
<li>Golden Cross Alert: 3 Stocks With Major Upside Potential</li>
</ul>
<div class="lb-trans"><ul>
<li>黄金交叉警报：三只具有重大上涨潜力的股票</li>
</ul>
</div><p>Read Our Latest Research Report on PFE</p>
<div class="lb-trans"><p>阅读我们关于 PFE 的最新研究报告</p>
</div><h2>Bristol Myers Squibb (BMY)</h2>
<div class="lb-trans"><h2>Bristol Myers Squibb (BMY)</h2>
</div><p>Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.</p>
<div class="lb-trans"><p>Bristol-Myers Squibb Company 在全球范围内发现、开发、许可、制造、营销、分销和销售生物制药产品。它提供用于血液学、肿瘤学、心血管、免疫学、纤维化和神经科学疾病的产品。该公司的产品包括 Eliquis，用于降低非瓣膜性心房颤动患者中风/全身栓塞的风险，以及治疗深静脉血栓/肺栓塞；Opdivo 用于多种抗癌适应症，包括膀胱癌、血液癌、结直肠癌、头颈癌、肾细胞癌、肝细胞癌、肺癌、黑色素瘤、胸膜间皮瘤、胃癌和食道癌；Pomalyst/Imnovid 用于多发性骨髓瘤；Orencia 用于活动性类风湿关节炎和银屑病关节炎；Sprycel 用于治疗费城染色体阳性慢性髓性白血病。</p>
</div><p>Read Our Latest Research Report on BMY</p>
<div class="lb-trans"><p>阅读我们关于 BMY 的最新研究报告</p>
</div><h2>AbbVie (ABBV)</h2>
<div class="lb-trans"><h2>AbbVie (ABBV)</h2>
</div><p>AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.</p>
<div class="lb-trans"><p>AbbVie Inc.在全球范围内发现、开发、制造和销售药物。该公司提供 Humira，一种用于自身免疫性和肠道贝赫切特病及脓皮病坏死的注射剂；Skyrizi 用于治疗中度至重度斑块型银屑病、银屑病性疾病和克罗恩病；Rinvoq 用于治疗类风湿关节炎和银屑病关节炎、强直性脊柱炎、特应性皮炎、轴性脊柱关节炎、溃疡性结肠炎和克罗恩病；Imbruvica 用于治疗成人血癌；Epkinly 用于治疗淋巴瘤；Elahere 用于治疗癌症；Venclexta/Venclyxto 用于治疗血癌。</p>
</div><p>Read Our Latest Research Report on ABBV</p>
<div class="lb-trans"><p>阅读我们关于 ABBV 的最新研究报告</p>
</div><h2>Gemini Therapeutics (GMTX)</h2>
<div class="lb-trans"><h2>Gemini Therapeutics (GMTX)</h2>
</div><p>Gemini Therapeutics, Inc., a clinical stage precision medicine company, engages in developing various therapeutic compounds for treating genetically defined age-related macular degeneration (AMD). Its lead candidate is GEM103, a recombinant form of the human complement factor H protein to treat dry AMD patients.</p>
<div class="lb-trans"><p>Gemini Therapeutics, Inc.是一家临床阶段的精准医学公司，致力于开发用于治疗基因定义的年龄相关性黄斑变性（AMD）的各种治疗化合物。其主要候选药物是 GEM103，一种重组人补体因子 H 蛋白，用于治疗干性 AMD 患者。</p>
</div><p>Read Our Latest Research Report on GMTX</p>
<div class="lb-trans"><p>阅读我们关于 GMTX 的最新研究报告</p>
</div><h2>Novo Nordisk A/S (NVO)</h2>
<div class="lb-trans"><h2>Novo Nordisk A/S (NVO)</h2>
</div><p>Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.</p>
<div class="lb-trans"><p>Novo Nordisk A/S 及其子公司从事药品的研究与开发、制造和分销，覆盖欧洲、中东、非洲、中国大陆、香港、台湾、北美及国际市场。它分为两个部门，糖尿病和肥胖护理，以及罕见疾病。</p>
</div><p>Read Our Latest Research Report on NVO</p>
<div class="lb-trans"><p>阅读我们关于 NVO 的最新研究报告</p>
</div><h2>Cytokinetics (CYTK)</h2>
<div class="lb-trans"><h2>Cytokinetics (CYTK)</h2>
</div><p>Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility.</p>
<div class="lb-trans"><p>Cytokinetics, Incorporated 是一家晚期生物制药公司，专注于发现、开发和商业化肌肉激活剂和抑制剂，作为潜在的治疗方案。该公司开发的小分子药物候选者主要旨在影响肌肉功能和收缩性。</p>
</div><p>Read Our Latest Research Report on CYTK</p>
<div class="lb-trans"><p>阅读我们关于 CYTK 的最新研究报告</p>
</div><h2>Further Reading</h2>
<div class="lb-trans"><h2>进一步阅读</h2>
</div><ul>
<li>MarketBeat's Top Five Stocks to Own in December 2025</li>
<li>RKLB, ASTS, TDG: Insiders are Selling These 3 Space Stocks</li>
<li>Instacart Got Caught Surveillance Pricing... But Investors Didn't Care</li>
<li>Broadcom Just Raised Its Dividend—But It’s Not the Only One Signaling Strength</li>
<li>Amazon Now Delivery Push Could Boost Its 2026 Outlook</li>
<li>5 Small-Cap Stocks to Watch in 2026 as Investors Rotate Out of Big Tech</li>
</ul>
<div class="lb-trans"><ul>
<li>MarketBeat 在 2025 年 12 月的五大股票推荐</li>
<li>RKLB、ASTS、TDG：内部人士正在出售这三只航天股票</li>
<li>Instacart 被监控定价...但投资者并不在意</li>
<li>Broadcom 刚刚提高了股息——但这并不是唯一一个发出强劲信号的公司</li>
<li>亚马逊现在的配送推动可能提升其 2026 年展望</li>
<li>2026 年值得关注的五只小型股，投资者正在从大型科技股中撤出</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Eli Lilly and Company Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1000 美元在 Eli Lilly and Company 吗？</h2>
</div><p>Before you consider Eli Lilly and Company, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Eli Lilly and Company 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Eli Lilly and Company wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买...而 Eli Lilly and Company 并不在名单上。</p>
</div><p>While Eli Lilly and Company currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然礼来目前在分析师中被评为适度买入，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

12 月 22 日值得关注的顶级制药股票